Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Carlos Amezcua Amezcua maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are split between 2 distinct examiners and 2 distinct art units, showing a distributed examination process for the biotechnology filings.
The busiest examiner is JUSTICE, GINA CHIEUN YU, who is responsible for 1 pending office action. This examiner handles a portion of the total 2 pending office actions. This distribution across different examiners and art units indicates that the portfolio is being reviewed under multiple sets of examiner criteria.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUSTICE, GINA CHIEUN YU | 1 | 55.6% | +8.4% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17291169 | PHARMACEUTICAL COMPOSITION WHICH COMPRISES THE COMBINATION OF A SELECTIVE INHIBITOR OF CYCLOOXYGENASE 2 AND A CARBAMATE DERIVED FROM GUAIFENESIN FOR TREATING PAIN, INFLAMMATION AND MUSCULAR CONTRACTION | BAEK, BONG-SOOK | 2d overdue |
| 17626888 | SYNERGISTIC COMBINATION OF S-KETOROLAC AND PREGABALIN IN A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROPATHIC PAIN | JUSTICE, GINA CHIEUN YU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17291169 | PHARMACEUTICAL COMPOSITION WHICH COMPRISES THE COMBINATION OF A SELECTIVE INHIBITOR OF CYCLOOXYGENASE 2 AND A CARBAMATE DERIVED FROM GUAIFENESIN FOR TREATING PAIN, INFLAMMATION AND MUSCULAR CONTRACTION | BAEK, BONG-SOOK | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17626888 | SYNERGISTIC COMBINATION OF S-KETOROLAC AND PREGABALIN IN A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROPATHIC PAIN | JUSTICE, GINA CHIEUN YU | 1617 | §103§112 | Non-Final OA | — | Pending | Jan 13, 2022 |
| 17291169 | PHARMACEUTICAL COMPOSITION WHICH COMPRISES THE COMBINATION OF A SELECTIVE INHIBITOR OF CYCLOOXYGENASE 2 AND A CARBAMATE DERIVED FROM GUAIFENESIN FOR TREATING PAIN, INFLAMMATION AND MUSCULAR CONTRACTION | BAEK, BONG-SOOK | 1611 | §103§112 | Final Rejection | 2d overdue | Pending | May 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial